Financial Data and Key Metrics Changes - The company reported a cash cost per pound of $29.90 based on 68,612 pounds of precipitated uranium and dried and drummed U3O8 produced [4] - The balance sheet remains strong with $698 million in cash, inventory, and equities at market prices and no debt [7] - The uranium inventory stands at 1,356,000 lbs U3O8 as of October 31, 2025, excluding an additional 199,000 lbs produced since restarting production [8] Business Line Data and Key Metrics Changes - The company launched the United States Uranium Refining and Conversion Corp, positioning itself as the only U.S. supplier with both uranium and UF6 production capabilities [3] - Production at Christensen Ranch has accumulated approximately 199,000 pounds of precipitated uranium and dried and drummed U3O8 since operations resumed [10] - The company is nearing operational status at Burke Hollow, with major construction milestones substantially complete [6] Market Data and Key Metrics Changes - The company continues to increase uranium inventory ahead of the Section 232 decision, benefiting from a tightening global market with a structural supply deficit [8] - The current uranium price backdrop is supported by growing global nuclear demand and favorable U.S. policy [9] - The supply deficit is expected to exceed 1.7 billion pounds by 2045 on a cumulative basis [15] Company Strategy and Development Direction - The company is focused on four key pillars of production growth: Powder River Basin, South Texas, Sweetwater, and Roughrider projects [10] - The development of the Ludeman ISR project is underway, which is fully licensed and permitted [12] - The company aims to build a fully American supply chain aligned with U.S. energy policy and defense needs [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the macro backdrop for uranium, citing strong bipartisan support for nuclear energy and the designation of uranium as a critical mineral [15] - The company is positioned to benefit from expected higher uranium prices due to a structural supply deficit [8] - Management highlighted the importance of the URNC initiative as a differentiator in the market, providing end-to-end capabilities from uranium resources to processing [37] Other Important Information - The company completed a $234 million public offering to accelerate the growth of its new business line while bolstering its balance sheet [7] - The company is 100% unhedged, maintaining full exposure ahead of the Section 232 investigation results [8] Q&A Session Summary Question: What are the next milestones for the URNC venture? - Management indicated that they are progressing well with state-level discussions and feasibility studies, aiming to deliver more information in fiscal Q2 [21][22] Question: What will the production cadence look like moving forward? - Management expects a step change in production cadence in fiscal Q3 and Q4 as Burke Hollow and additional header houses at Christensen Ranch come online [27] Question: Can you provide guidance on the potential production timelines for the Ludeman project? - Management stated that Ludeman is well-situated for development and will follow a similar approach to Christensen Ranch, with production ramp-up planned [44] Question: What is the expected timeline for the Strategic Uranium Reserve release? - Management is optimistic about the potential for an expanded Strategic Uranium Reserve and expects to hear recommendations from the president by December or early January [52] Question: What is the estimated spend required to advance the URNC initiatives for fiscal year 2026? - Management indicated that current spending is modest and the company is adequately capitalized for the work needed at this stage [76]

Financial Data and Key Metrics Changes - Total radiopharmaceutical revenues for Q3 2025 were $1.3 million, an 18% increase compared to Q3 2024, and year-to-date revenues reached $3.6 million, a 24% increase versus 2024 [31] - Year-to-date total operating expenses increased by $16.5 million, or 84%, from $19.7 million in 2024 to $36.2 million in 2025 [32] - Net loss from operations for year-to-date 2025 was $34.9 million, compared to $18.7 million for the same period in 2024 [32] - Cash balance as of September 30, 2025, was $113.9 million, reflecting net proceeds of approximately $56 million from common stock issuance during Q3 2025 [34] Business Line Data and Key Metrics Changes - The multi-isotope plant in South Africa is currently enriching silicon-28 and has shipped commercial samples validated for isotopic purity [4] - The nuclear medical segment has seen growth in volumes and doses sold, leading to increased revenues [9] - The carbon plant is expected to start producing carbon-14, with the first full batch anticipated in January 2026 [8] Market Data and Key Metrics Changes - The acquisition of Renergen is expected to enhance the company's capabilities in the semiconductor gas vertical, with regulatory approvals nearly complete [5] - The company has secured a contract for silicon-28 and aims to fulfill customer orders by 2026 [4] Company Strategy and Development Direction - The company aims to diversify its operations beyond South Africa and expand its radiopharmaceutical footprint globally [70] - Quantum Leap Energy (QLE) plans to secure the nuclear supply chain and has raised $64.3 million via convertible notes to support its initiatives [13][14] - The acquisition of Skyline Builders is part of a strategy to secure critical material supply chains essential for the U.S. and ASP Isotopes [21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the operational capabilities and customer relationships, emphasizing the positive feedback from customers regarding the enrichment processes [38] - The focus for the next six months includes completing the Renergen acquisition and achieving operational de-risking by the end of Q1 2026 [39][40] - The company is committed to providing further guidance on revenue projections as clarity improves internally [52][53] Other Important Information - The company is planning to begin construction of new plants in various locations, including Iceland, the U.S., and the U.K., during 2026 [29] - The first quantum enrichment plant is producing ytterbium-176, with commercial quantities expected in the first half of 2026 [7] Q&A Session Summary Question: Can you talk about the delays in shipping Silicon-28? - Delays were due to the complexity of the production process and modifications made after customer visits, which improved the customer-supplier relationship [37][38] Question: When do you expect to achieve operational de-risking in respect of Renergen? - Operational de-risking is expected by the end of Q1 2026, focusing on completing phase 1C of the project [39][40] Question: When will the company begin to recognize revenue in its isotopes enrichment segment? - Revenue recognition for carbon is expected by the end of December, with silicon isotopes anticipated in the first half of 2026 [41][42] Question: What did the customers say about our samples of both Ytterbium and Silicon? - Customers were pleased with the results of the samples, indicating that the technology works effectively [44][47] Question: Is the $50-$70 million revenue opportunity in 2026 and 2027 still valid? - The company is not changing previous guidance and will provide updates as more clarity is achieved [49][50][52] Question: Can you help us understand the capital commitment in 2026 for new facilities? - Detailed breakdowns of capital commitments and revenue opportunities will be provided in future updates [54][55] Question: Can you discuss the opportunity for LEU Plus? - LEU Plus is a new focus based on customer inquiries, aimed at increasing power density and extending the life of existing nuclear power plants [56][60] Question: Should we model the $3 million revenue from Skyline Builders going forward? - The revenue from Skyline Builders is not expected to continue, as the focus will shift away from construction [64][66]